Rebastinib (DCC-2036) | B1619

DCC-2036 (Rebastinib) is an inhibitor of Bcr-Abl with IC50 of 0.8 nM and 4 nM for Abl1(WT) and Abl1(T315I), respectively.

DCC-2036 (Rebastinib) is an inhibitor of Bcr-Abl with IC50 of 0.8 nM and 4 nM for Abl1(WT) and Abl1(T315I), respectively.

B1619 | Rebastinib (DCC-2036) DataSheet

Alternate Name/Synonyms: DCC-2036; DCC-2036; DCC2036; Bcr-Abl inhibitor; Bcr-abl inhibitor; 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide

Appearance: Solid

Formulation: N/A

CAS Number: 1020172-07-9

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₃₀H₂₈FN₇O₃

Molecular Weight: 553.59

Cell-Permeable?: Yes

Purity: >98%

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A Bcr-Abl inhibitor

MDL Number: MFCD19443646

PubChem CID: 25066467

SMILES: CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5

InChi: 1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)

InChi Key: WVXNSAVVKYZVOE-UHFFFAOYSA-N